October 9, 2024
TOPLINE: A recent analysis, evaluating an intervention in which patients with non–small cell lung cancer (NSCLC) used a wearable device to help monitor exercise post-surgery, found […]
October 9, 2024
RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a […]
October 9, 2024
Thanks to the continuously improving treatment options for cancer, the number of cancer survivors is increasing, and a large proportion of survivors is confronted with the […]
October 8, 2024
Breast cancer incidence has been on the rise, particularly among White women under age 50, but breast cancer deaths — for some, but not all, populations […]
October 8, 2024
TOPLINE: Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival was 55.9 […]
October 8, 2024
Some breast cancer types are more likely than others to recur. Researchers have known this for more than a decade. But they have long wondered why. […]
October 7, 2024
TOPLINE: Stereotactic body radiotherapy (SBRT) and hypofractionated conventional radiotherapy led to similar tumor control and survival outcomes at 3 years in patients with peripheral and central […]
October 4, 2024
WASHINGTON — MRI-guided stereotactic body radiotherapy (SBRT) showed sustained benefits over CT-guided SBRT for prostate cancer, in a study. Amar Kishan, MD, of UCLA Health, presented […]
October 4, 2024
RIO DE JANEIRO — Adding isatuximab, or Isa (Sarclisa, Sanofi-Aventis), to bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed, transplant-ineligible multiple […]